| Henne-Bruns, Doris |
MIPSA, NCT03044223: Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis |
|
|
| Recruiting | N/A | 100 | Europe | | University of Ulm | Pseudomonas Infections, Pseudomonas Septicemia, Pseudomonas; Pneumonia, Pseudomonal Bacteraemia, Pseudomonas Urinary Tract Infection, Pseudomonas Gastrointestinal Tract Infection, Sepsis, Sepsis, Severe, Critically Ill | 11/25 | 12/26 | | |
| Wöhrle, Jochen |
NCT05114850: Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve® |
|
|
| Recruiting | N/A | 450 | Europe | | P+F Products + Features GmbH | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Insufficiency, Heart Failure, Heart Diseases, Heart Valve Diseases | 12/25 | 12/28 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
CLEARANCE, NCT04298723: Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding. |
|
|
| Recruiting | N/A | 530 | Europe | Percutaneous closure of the LAA (Watchman / Watchman FLX) | Jena University Hospital | Atrial Fibrillation (AF), Intracranial Bleed | 06/27 | 06/27 | | |
| Holl, Reinhard |
| Active, not recruiting | 2 | 138 | Europe | Verapamil SR 120 mg, VeraHEXAL KHK 120 mg, Isoptin retard 120 mg, Placebo, Matching Placebo for Verapamil SR 120 mg | Medical University of Graz, Juvenile Diabetes Research Foundation | Diabetes Mellitus, Type 1 | 05/25 | 05/26 | | |
NCT02062164: Weight Loss Surgery in Adolescents With Extreme Obesity |
|
|
| Active, not recruiting | N/A | 66 | Europe | bariatric surgery, conservative care | Prof. Dr. Martin Wabitsch, University of Witten/Herdecke, Charite University, Berlin, Germany, University of Leipzig, Universität Duisburg-Essen | Obesity, Extreme Obesity | 04/18 | 01/28 | | |
| Recruiting | N/A | 6000 | Europe | | University of Cambridge, Innovative Medicines Initiative, Juvenile Diabetes Research Foundation, The Leona M. and Harry B. Helmsley Charitable Trust | Type 1 Diabetes Mellitus | 10/22 | 10/22 | | |
NCT01632098: Economic Aspects of Extreme Obesity in Adolescent |
|
|
| Completed | N/A | 429 | Europe | | University of Ulm, University of Witten/Herdecke, Charite University, Berlin, Germany, University of Leipzig, Universität Duisburg-Essen, Helmholtz Zentrum München | Obesity, Extreme Obesity | 07/23 | 07/23 | | |
NCT01662271: Course of Obesity and Extreme Obesity in Adolescents |
|
|
| Completed | N/A | 429 | Europe | | Prof. Dr. Martin Wabitsch, University of Witten/Herdecke, Charite University, Berlin, Germany, University of Leipzig, Universität Duisburg-Essen, Helmholtz Zentrum München | Obesity, Extreme Obesity | 07/23 | 07/23 | | |
| Seufferlein, Thomas |
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Completed | 1/2 | 167 | Europe | CAN04, Cisplatin, Gemcitabine, Nab-paclitaxel, Carboplatin, Pemetrexed | Cantargia AB | Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer | 03/24 | 03/24 | | |
| Recruiting | 1/2 | 18 | Europe | Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml) | AIO-Studien-gGmbH, Deutsche Krebshilfe e.V., Bonn (Germany) | Chemo-refractory Colorectal Carcinoma | 06/25 | 06/25 | | |
ARCHES, NCT05041283: Impact of Artificial Intelligence-based Patient Reinforcement on Quality of Colonoscopy |
|
|
| Recruiting | N/A | 258 | Europe | Chatbot, Phone call | University of Ulm | Bowel Preparation | 02/22 | 02/22 | | |
| Recruiting | N/A | 5000 | Europe | | ClarData | COVID-19 | 12/22 | 06/23 | | |
| Recruiting | N/A | 200 | Europe | Liquid Biopsy | Ludwig-Maximilians - University of Munich, Hoffmann-La Roche | Pancreas Cancer | 12/24 | 12/25 | | |
| Recruiting | N/A | 5000 | Europe | | University of Ulm | Pancreas Adenocarcinoma, Pancreas Cancer | 10/28 | 10/29 | | |
NCT04686409: App-based Symptom Tracking After Corona Vaccination (CoCoV) |
|
|
| Not yet recruiting | N/A | 500 | Europe | COVID-19 vaccines | University of Ulm | Adverse Events in COVID-19 Vaccination | 01/22 | 08/22 | | |
| Gebhard, Florian F |
MIPSA, NCT03044223: Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis |
|
|
| Recruiting | N/A | 100 | Europe | | University of Ulm | Pseudomonas Infections, Pseudomonas Septicemia, Pseudomonas; Pneumonia, Pseudomonal Bacteraemia, Pseudomonas Urinary Tract Infection, Pseudomonas Gastrointestinal Tract Infection, Sepsis, Sepsis, Severe, Critically Ill | 11/25 | 12/26 | | |
| Contact, Use Central |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
| Recruiting | 3 | 200 | RoW | Patiromer Powder for Oral Suspension (Part A), Placebo (Part B), Patiromer Powder for Orals Suspension (Part B) | Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd | Hyperkalemia, Renal Insufficiency, Chronic | 12/25 | 03/26 | | |
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705) |
|
|
| Active, not recruiting | 3 | 136 | US | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo | CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI) | Graft Versus Host Disease (GVHD) | 06/24 | 12/24 | | |
| Active, not recruiting | 3 | 126 | Europe, Japan, US, RoW | human immunoglobulin G, IgPro20, Hizentra, Placebo | CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406 | Dermatomyositis | 05/28 | 05/28 | | |
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS |
|
|
| Recruiting | 3 | 177 | Canada, US | IgPro20, HIZENTRA®, Placebo | CSL Behring | Post-COVID Postural Orthostatic Tachycardia Syndrome | 09/27 | 09/27 | | |
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema |
|
|
| Active, not recruiting | 3 | 20 | Europe, Canada, US, RoW | CSL312, Garadacimab | CSL Behring | Hereditary Angioedema (HAE) | 11/26 | 11/26 | | |
| Terminated | 3 | 194 | Europe, Canada, US, RoW | Clazakizumab, Physiologic saline solution | CSL Behring, ICON Clinical Research | Antibody-mediated Rejection | 04/24 | 04/24 | | |
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) |
|
|
| Recruiting | 3 | 35 | Canada, US, RoW | CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec | CSL Behring | Hemophilia B | 10/28 | 10/28 | | |
MODULAATE, NCT03805789 / 2018-000329-29: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant |
|
|
| Recruiting | 2/3 | 310 | Europe, Japan, US, RoW | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor, Placebo | CSL Behring, Commercial/Industry, CSL | Acute-graft-versus-host Disease | 09/25 | 03/27 | | |
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis |
|
|
| Recruiting | 2/3 | 2310 | Europe, Canada, Japan, US, RoW | CSL300, Clazakizumab, Placebo | CSL Behring | Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease | 12/28 | 12/28 | | |
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® |
|
|
| Active, not recruiting | 2 | 81 | Europe, RoW | Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL | Astellas Pharma Europe Ltd. | Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation | 10/15 | 12/25 | | |
KOR-PED-202, NCT06593392: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus |
|
|
| Not yet recruiting | 2 | 18 | Europe | Difelikefalin | Vifor Fresenius Medical Care Renal Pharma | Pruritus, Chronic Kidney Diseases | 08/29 | 08/29 | | |
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age |
|
|
| Recruiting | 2 | 38 | US | TARA-002 | Protara Therapeutics | Lymphatic Malformation | 12/25 | 05/26 | | |
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 127 | Canada, US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 05/30 | 08/30 | | |
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects |
|
|
| Terminated | 1 | 52 | Europe | CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo | CSL Behring | Immune Complex-mediated Autoimmune Diseases | 03/23 | 03/23 | | |
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge |
|
|
| Completed | 1 | 40 | Europe | CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo | CSL Behring | Healthy Volunteers | 07/23 | 07/23 | | |
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers |
|
|
| Completed | 1 | 78 | Europe | Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo | CSL Behring | Asthma | 11/23 | 11/23 | | |
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) |
|
|
| Completed | 1 | 10 | US | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 09/24 | 09/24 | | |
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) |
|
|
| Completed | 1 | 12 | Europe, US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 09/24 | 10/24 | | |
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects |
|
|
| Recruiting | 1 | 60 | RoW | CSL040, Placebo | CSL Behring | Disease Driven by Complement Activation | 04/25 | 04/25 | | |
| Completed | N/A | 80 | Europe, US | | Protara Therapeutics | Intestinal Failure-associated Liver Disease | 06/23 | 06/23 | | |
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B |
|
|
| Recruiting | N/A | 500 | US | HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX) | CSL Behring | Hemophilia B | 08/43 | 08/43 | | |
| Schumann, Christian |
NCT04413201: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC |
|
|
| Active, not recruiting | 4 | 34 | Europe | Afatinib, Osimertinib | Michael Hopp, Boehringer Ingelheim | Non-squamous NSCLC | 06/24 | 06/24 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
| Recruiting | 2 | 700 | Europe | | ResMed, CRI-The Clinical Research Institute, Munich | Sleep Apnea, Sleep Disorder, Sleep Apnea Syndromes, Sleep-disordered Breathing | 03/21 | 07/21 | | |
| Ettrich, Thomas J |
| Completed | 3 | 430 | Europe | Ramucirumab, TAS 102 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH | Colorectal Cancer | 07/24 | 07/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
| Active, not recruiting | 3 | 450 | Europe, Japan, US, RoW | Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf | Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health | Gastro-Oesophageal Cancer | 06/25 | 06/26 | | |
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) |
|
|
| Recruiting | 3 | 507 | Europe | mFOLFOX6, Folinic acid, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Folinic acid, Oxaliplatin, 5-FU, Irinotecan, FOLFIRI, Folinic acid, 5-FU, CAPOX, Capecitaine, Oxaliplatin | Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Colorectal Cancer | 11/27 | 11/30 | | |
RAMIRIS, NCT03081143 / 2015-005171-24: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy |
|
|
| Active, not recruiting | 2/3 | 429 | Europe | FOLFIRI, Ramucirumab, Paclitaxel | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Advanced Gastric or EGJ Cancer | 12/25 | 12/25 | | |
| Active, not recruiting | 2 | 93 | Europe | Arm NaI-IRI + 5-FU + Leucovorin (Arm A), Arm Cisplatin + Gemcitabine (Arm B) | AIO-Studien-gGmbH, Servier, Institut für Klinisch-Onkologische Forschung der Krankenhaus Nordwest GmbH | Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract, Adenocarinoma Locally Advanced, Non-Resectable Hepatocellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Extrahepatic Bile Duct Carcinoma | 01/22 | 01/25 | | |
| Recruiting | 2 | 35 | Europe | FOLFIRI Protocol, SCO-101 | Scandion Oncology A/S, TFS Trial Form Support | Metastatic Colorectal Cancer | 06/22 | 06/22 | | |
FUTURE, NCT06722183: Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities |
|
|
| Not yet recruiting | 2 | 33 | Europe | Futibatinib orally administered, Tislelizumab (i.v. 200mg) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler | Colorectal Cancer | 06/27 | 06/27 | | |
NCT04511455: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment |
|
|
| Completed | 2 | 22 | Europe | Cabozantinib | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen | Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | 12/24 | 12/24 | | |
PANTAX-Ib, NCT04652206: Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. |
|
|
| Recruiting | 1/2 | 18 | Europe | SCO-101, Gemcitabine, Nab paclitaxel | Scandion Oncology A/S, Alcedis GmbH | Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Inoperable Disease, Localized Pancreatic Adenocarcinoma | 03/22 | 05/22 | | |
| Doehner, Konstanz |
| Active, not recruiting | 1/2 | 96 | Europe | INCB018424/CC-4047 | University of Ulm | Primary Myelofibrosis, Secondary Myelofibrosis, PMF, SMF, Post-PV MF, Post-ET MF | 04/24 | 04/26 | | |
| Buske, Christian |
| Completed | 3 | 202 | Europe | Dexamethasone, Rituximab, Cyclophosphamide, Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib | University of Ulm, Centre Hospitalier de Lens (Co-Sponsor) | Waldenström's Macroglobulinemia | 11/18 | 04/24 | | |
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 |
|
|
| Recruiting | 3 | 790 | Europe | Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin | The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Follicular Lymphoma | 11/28 | 04/34 | | |
| Recruiting | 3 | 100 | Europe | Standard, Experimental, Rituximab, Obinutuzumab | Heidelberg University | Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a | 12/26 | 12/29 | | |
NCT02131753: Therapy Optimisation for the Treatment of Hairy Cell Leukemia |
|
|
| Recruiting | 2/3 | 210 | Europe | Cladribine s.c. injection, HCL treatment, Litak(R), 2-CdA | University of Giessen | Hairy Cell Leukemia | 12/25 | 12/27 | | |
Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden |
|
|
| Active, not recruiting | 2 | 98 | Europe | Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO® | Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer | Follicular Lymphoma | 09/23 | 05/26 | | |
| Active, not recruiting | 2 | 53 | Europe | Ibrutinib / Bortezomib / Rituximab, Imbruvica / Velcade / Mabthera | Christian Buske, University of Ulm, ClinAssess GmbH, Zentrum für Klinische Studien Ulm, Hoffmann-La Roche, Johnson & Johnson | Waldenstrom Macroglobulinemia | 11/22 | 09/29 | | |
| Active, not recruiting | 2 | 56 | Europe | Obinutuzumab, GA101 | Christian Buske, University of Ulm, Optimapharm, Zentrum für Klinische Studien Ulm, X-act Cologne Clinical Research GmbH, Roche Pharma AG | Marginal Zone Lymphoma | 06/24 | 11/28 | | |
| Active, not recruiting | 2 | 36 | Europe | Copanlisib, Aliqopa, Rituximab, Truxima | Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer | Marginal Zone Lymphoma | 06/24 | 12/29 | | |
VIWA-1, NCT05099471: Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia |
|
|
| Not yet recruiting | 2 | 80 | NA | Venetoclax; Rituximab, Venetoclax / Rituximab, DRC, Dexamethasone / Rituximab / Cyclophosphamide | University of Ulm, Ludwig-Maximilians - University of Munich, Zentrum für Klinische Studien Ulm, AbbVie, Pfizer, University Hospital Schleswig-Holstein, Campus Kiel | Waldenstrom Macroglobulinemia | 01/28 | 12/32 | | |
NCT04263480: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia |
|
|
| Recruiting | 2 | 99 | Europe | Carfilzomib + Ibrutinib, Ibrutinib | Christian Buske, Amgen, Janssen, LP | Waldenstrom Macroglobulinemia | 02/28 | 02/28 | | |
NCT04268277: Pembrolizumab in MarginalzoneLymphoma a MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY |
|
|
| Terminated | N/A | 22 | Europe | Rituximab, Truxima, Pembrolizumab, Keytruda | University of Ulm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Merck Sharp & Dohme LLC, Celltrion Healthcare Co., LTD | Marginal Zone Lymphoma | 12/24 | 12/24 | | |
| Karakas, Mahir |
| Completed | 4 | 1105 | Europe | Iron, Saline, salin | Universitätsklinikum Hamburg-Eppendorf, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Charite University, Berlin, Germany | Systolic Heart Failure, Iron Deficiency | 05/24 | 05/24 | | |
| Terminated | 3 | 8 | Europe | Ferric carboxymaltose, Saline | Dr. med. Mahir Karakas | Cardiovascular Diseases, Anemia, Iron-deficiency, Acute Myocardial Infarction, Atrial Fibrillation, Systolic Heart Failure | 12/21 | 12/21 | | |
| Terminated | 2 | 16 | Europe | Adrecizumab (HAM 8101), Placebo, Saline | Universitätsklinikum Hamburg-Eppendorf | COVID-19 | 08/23 | 11/23 | | |
| Koenig, Wolfgang |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Michels, Sebastian |
| Terminated | 2 | 22 | Europe | ERDAFITINIB, JNJ -42756493, WHO NUMBER 10147 | Lung Cancer Group Cologne | Lung Cancer, NSCLC, Pulmonary Neoplasm, Squamous Cell Lung Cancer, NSCLC Stage IV | 09/22 | 10/22 | | |
| Recruiting | 2 | 50 | Europe | Osimertinib, Tagrisso, Pemetrexed, Cisplatin, Carboplatin | Goethe University | NSCLC Stage IIIB, NSCLC Stage IV | 11/23 | 11/26 | | |
| Doehner, Konstanze |
ROP-ET, NCT06514807: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients |
|
|
| Active, not recruiting | 3 | 117 | Europe, RoW | Ropeginterferon alfa-2b (BESREMi®) | AOP Orphan Pharmaceuticals AG | Essential Thrombocythaemia | 03/28 | 03/28 | | |
| Wabitsch, Martin |
NCT06484868: Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy |
|
|
| Recruiting | 4 | 12 | Europe | Metreleptin | Amryt Pharma | Partial Lipodystrophy | 09/27 | 09/27 | | |
| Recruiting | 3 | 300 | Europe, Canada, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Weight Gain | 05/27 | 06/27 | | |
NCT06502990: Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy |
|
|
| Recruiting | 3 | 15 | Europe | Metreleptin | Amryt Pharma | Generalized Lipodystrophy | 09/26 | 09/26 | | |
NCT02062164: Weight Loss Surgery in Adolescents With Extreme Obesity |
|
|
| Active, not recruiting | N/A | 66 | Europe | bariatric surgery, conservative care | Prof. Dr. Martin Wabitsch, University of Witten/Herdecke, Charite University, Berlin, Germany, University of Leipzig, Universität Duisburg-Essen | Obesity, Extreme Obesity | 04/18 | 01/28 | | |
NCT01632098: Economic Aspects of Extreme Obesity in Adolescent |
|
|
| Completed | N/A | 429 | Europe | | University of Ulm, University of Witten/Herdecke, Charite University, Berlin, Germany, University of Leipzig, Universität Duisburg-Essen, Helmholtz Zentrum München | Obesity, Extreme Obesity | 07/23 | 07/23 | | |
NCT01662271: Course of Obesity and Extreme Obesity in Adolescents |
|
|
| Completed | N/A | 429 | Europe | | Prof. Dr. Martin Wabitsch, University of Witten/Herdecke, Charite University, Berlin, Germany, University of Leipzig, Universität Duisburg-Essen, Helmholtz Zentrum München | Obesity, Extreme Obesity | 07/23 | 07/23 | | |
| Recruiting | N/A | 2000 | Europe | | University of Ulm, German Federal Ministry of Education and Research | Stem Cell Transplant, Stem Cell Transplantation, Oncological Outcomes, Oncological Patients, Oncological Children, Fertility, Fertility Protection, Endocrinological Late-effects, Paediatric Oncology, CAYA, Survivors | 11/44 | 11/44 | | |
| Recruiting | N/A | 5000 | Europe, RoW | | University of Ulm, Sorbonne University, University Hospital, Lille, University of Cambridge, Endocrinology Research Centre, Moscow, University of Leipzig, University of Amsterdam, Dokuz Eylul University, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Rome Tor Vergata, University of Pisa, University of Santiago de Compostela, Università degli Studi del Piemonte Orientale Amedeo Avogadro, University Hospital Muenster, Szeged University, Centro Hospitalar do Porto, University Medical Centre Ljubljana, Medical University of Vienna, Ostschweizer Kinderspital | Lipodystrophy Acquired, Lipodystrophy Congenital | 01/68 | 01/68 | | |
| Coburger, Jan |
| Recruiting | N/A | 90 | Europe | resection with help of 3D ultrasound | University of Ulm, Brainlab AG | Residual Tumor | 12/24 | 03/25 | | |
LoG-Glio, NCT02686229: Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas |
|
|
| Recruiting | N/A | 300 | Europe | no interventions | University of Ulm, Charite University, Berlin, Germany | Glioma | 12/26 | 12/36 | | |
| Reister, Frank |
NCT03855735: TeamBaby - Safe, Digitally Supported Communication in Obstetrics and Gynecology |
|
|
| Completed | N/A | 424 | Europe | TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2) | Jacobs University Bremen gGmbH, German Coalition for Patient Safety (Aktionsbündnis Patientensicherheit), Techniker Krankenkasse, University Hospital Ulm, The German Innovation Fund (Innovationsfonds), Goethe University | Pregnancy Related | 03/23 | 03/23 | | |
| Mendler, Marc |
| Active, not recruiting | 3 | 1065 | Europe, RoW | closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) | University Hospital Tuebingen | Infant,Premature | 12/26 | 12/26 | | |
| CAILLARD-OHLMANN, Sophie |
| Recruiting | N/A | 150 | Europe, RoW | No Intervention | Takeda | Cytomegalovirus (CMV) | 04/25 | 04/25 | | |
| Kessler, Mirjam |
TriCLASP, NCT04614402: Transcatheter Repair of Tricuspid Regurgitation With Edwards PASCAL Transcatheter Valve Repair System |
|
|
| Active, not recruiting | N/A | 300 | Europe | Edwards PASCAL Transcatheter Valve Repair System, Edwards PASCAL Precision Transcatheter Valve Repair System | Edwards Lifesciences | Tricuspid Valve Insufficiency | 04/23 | 03/28 | | |
| Recruiting | N/A | 500 | Europe | IASD Implant | Corvia Medical | Heart Failure | 07/26 | 07/28 | | |
| Recruiting | N/A | 750 | Europe, Canada, US, RoW | Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) | Corvia Medical | Heart Failure, Heart Failure, Diastolic | 05/25 | 03/31 | | |
| Recruiting | N/A | 500 | Europe, Canada, US | MitraClip™ device implantation, Mitral Valve Repair Surgery | Abbott Medical Devices | Mitral Valve Regurgitation | 04/26 | 04/34 | | |
| Recruiting | N/A | 1000 | Europe | PASCAL leaflet repair system | LMU Klinikum | Tricuspid Regurgitation | 05/23 | 05/24 | | |
| Markovic, Sinisa |
| Terminated | 3 | 8 | Europe | Ferric carboxymaltose, Saline | Dr. med. Mahir Karakas | Cardiovascular Diseases, Anemia, Iron-deficiency, Acute Myocardial Infarction, Atrial Fibrillation, Systolic Heart Failure | 12/21 | 12/21 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
| Dorst, Johannes |
IVITOC, NCT04881682: Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
|
|
| Recruiting | 2 | 20 | Europe | Immunoadsorption, Immunoglobulins | University of Ulm, Miltenyi Biomedicine GmbH | CIDP | 03/26 | 03/26 | | |
| Recruiting | N/A | 3000 | Europe | Neurofilament light chain | Charite University, Berlin, Germany, Boris Canessa ALS Stiftung | Amyotrophic Lateral Sclerosis, Motor Neuron Disease | 12/24 | 12/24 | | |
| Recruiting | N/A | 20 | Europe | Immunoadsorption, Plasma Exchange | University of Ulm, DiaMed GmbH | GBS | 05/25 | 05/25 | | |
KETO-ALS, NCT04820478: Efficacy and Tolerability of Beta Hydroxybutyrate Ester in Patients With Amyotrophic Lateral Sclerosis (ALS) |
|
|
| Recruiting | N/A | 76 | Europe | Beta Hydroxybutyrate Ester (KetoneAid KE4), Placebo | University of Ulm | Amyotrophic Lateral Sclerosis | 10/25 | 10/25 | | |
| Recruiting | N/A | 392 | Europe | Ultra-high-caloric fatty diet, Placebo | University of Ulm | Amyotrophic Lateral Sclerosis | 06/27 | 06/27 | | |
| Essers, Jochen |
PREMOD2FU, NCT03476980: Two Year Developmental Follow-up for PREMOD2 Trial (Premature Infants Receiving Milking or Delayed Cord Clamping) |
|
|
| Recruiting | N/A | 1200 | Europe, Canada, US | Randomized to Umbilical Cord Milking at birth, UCM, Randomized to Delayed Cord Clamping at birth, DCC | Sharp HealthCare, Sharp Mary Birch Hospital for Women & Newborns, Loma Linda University, University of Pittsburgh, Providence Hospital, University of Alabama at Birmingham, University of Alberta, University College Cork, University of Ulm, Christiana Care Health Services, Thrasher Research Fund, Sharp Grossmont Hospital, University of Utah, University of Mississippi Medical Center, PIH Health Good Samaritan Hospital, University of California, Irvine, Children's Hospital Medical Center, Cincinnati, John H. Stroger Hospital, St. Louis University, LAC+USC Medical Center | Neurodevelopmental Abnormality | 12/24 | 12/24 | | |
